Skip to main content

Personal Genomes: Accessing, Sharing, and Interpretation

Cover image for Research Topic "Personal Genomes: Accessing, Sharing, and Interpretation"
150kviews
Editorial04 June 2021
Editorial: Personal Genomes: Accessing, Sharing, and Interpretation

genomics revolution. This genomics revolution is not exempt from challenges, in part amplified by lack of standards (ethical, legal, and technological), slow translation of knowledge to the clinic, and unequal access of personal genome benefits for all.As the vast majority of reference data in public databases continue to be of European ancestries, existing health disparities between rich and poor are likely to continue. In parallel, access to directto-consumer personal genetic testing continues to increase the public's appetite for genotyping and ancestry testing, resulting in greater number of enquiries with clinicians and public healthcare systems. This has left many medical professionals unprepared and unable to harness the wave of patient-focused healthcare and demand for data sharing -data sharing which is crucial for establishing better, more precise tools for diagnosis and treatment. However, sharing also opens the door for privacy concerns as secure access of genome data and metadata cannot always be guaranteed. Increased legal protection and institutional support are likely to keep promoting positive impact for diverse participation.On April 11-12 2019, we helped organise the First Personal Genomes Conference at the Wellcome Genome Campus, Hinxton, UK, to discuss issues around personal genomic data access, sharing and interpretation (Rubin and Glusman, 2019) In conclusion, we observe that although general access to personal genome data is becoming more widespread, the benefits of such advances are being deployed unevenly. Tools are being implemented that help facilitate the interpretation of personal genomic data and their increased, more secure sharing. We see these advances being undertaken both by academic and industry sectors. But a number of ethical challenges persist, including how to return data to participants in different regions of the world, or how to access direct-to-consumer services and raw data for personal genome analysis, which still remain biased depending on the individual's local jurisdiction. It is our wish to raise awareness about these hurdles and to bring all stakeholders involved into fruitful discussions to promote greater access to the benefits of personal genomics for all.

2,921 views

1 citations

MINI REVIEW
22 July 2020
A Review on the Challenges in Indian Genomics Research for Variant Identification and Interpretation
Sandhya Kiran Pemmasani, 3 more and Anuradha Acharya

17,185 views

17 citations

BRIEF RESEARCH REPORT
30 June 2020
Workflow for the Implementation of Precision Genomics in Healthcare
Sanja Mehandziska, 7 more and Goran Kungulovski

8,061 views

6 citations

Impute.me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores
To date, interpretation of genomic information has focused on single variants conferring disease risk, but most disorders of major public concern have a polygenic architecture. Polygenic risk scores (PRS) give a single measure of disease liability by summarising disease risk across hundreds of thousands of genetic variants. They can be calculated in any genome-wide genotype data-source, using a prediction model based on genome-wide summary statistics from external studies. As genome-wide association studies increase in power, the predictive ability for disease risk will also increase. While PRS are unlikely ever to be fully diagnostic, they may give valuable medical information for risk stratification, prognosis, or treatment response prediction. Public engagement is therefore becoming important on the potential use and acceptability of PRS. However, the current public perception of genetics is that it provides ‘Yes/No’ answers about the presence/absence of a condition, or the potential for developing a condition, which in not the case for common, complex disorders with of polygenic architecture. Meanwhile, unregulated third-party applications are being developed to satisfy consumer demand for information on the impact of lower risk variants on common diseases that are highly polygenic. Often applications report results from single SNPs and disregard effect size, which is highly inappropriate for common, complex disorders where everybody carries risk variants. Tools are therefore needed to communicate our understanding of genetic predisposition as a continuous trait, where a genetic liability confers risk for disease. Impute.me is one such a tool, whose focus is on education and information on common, complex disorders with polygenetic architecture. Its research-focused open-source website allows users to upload consumer genetics data to obtain PRS, with results reported on a population-level normal distribution. Diseases can only be browsed by ICD10-chapter-location or alphabetically, thus prompting the user to consider genetic risk scores in a medical context of relevance to the individual. Here we present an overview of the implementation of the impute.me site, along with analysis of typical usage-patterns, which may advance public perception of genomic risk and precision medicine.

29,141 views

64 citations

Personal genomic data and the related health data are valuable resources for both public-funded research, and for-profit entities in development of new drugs, therapies and diagnostic tests. In order to access to large datasets, pharmaceutical and biotech companies have developed partnerships with public and private entities such as Direct-to-Consumer (DTC) genetic testing companies to buy genomic and health related databases collected from research participants and customers. Although individuals mainly support data sharing for research purposes, the for-profit nature of such data sharing raises some questions regarding the rights of the data subjects and fairness in sharing benefits. In response, a new generation of sequencing and data sharing startups such as Nebula Genomics, LunaDNA and EncrypGen are emerging which aim for leaving the data control in the hands of each individual customer. In particular, such so-called “DNA data marketplaces” allow individuals to receive various types of monetary incentives to sequence their genome and share it with interested commercial parties. This paper aims to provide an exploratory and critical review of the ethical challenges related to establishing such marketplaces for genomic and health data sharing. In the view of the growing number of startups developing such marketplaces, a thorough analysis of the relevant ethical concerns is timely and needed.

15,196 views

42 citations